lenvatinib,sunitinib,everolimus,pembrolizumab
merck,pfizer,eisai
['clear trial']
4-yfu of clear trial te. hutson orr 71%, 18.3% cr significant pfs in all imdc risk groups os benefit inter/poor imdc risk group. #asco23 
On the road! Medical Oncologist & Prof @AnkaraUni | GU cancer expert  🔬| Diversity & Equity 📢 Advocate 💫  🌍 #Oncology #GenitourinaryCancer